Announcement PDF Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 1 / 8 Announcement Summary Entity name RADIOPHARM THERANOSTICS LIMITED Announcement Type New announcement Date of this announcement Thursday September 17, 2026 The +securities to be quoted are: Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue. Appendix 3B issued 24 July 2026 including new class of option to be quoted Total number of +securities to be quoted ASX +security code Security description Number of +securities to be quoted Issue date RAD ORDINARY FULLY PAID 40,000,000 17/09/2026 New class - code to be confirmed OPTION EXPIRING 31-JUL-2029 EX 0.018 448,839,531 17/09/2026 Refer to next page for full details of the announcement Other Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 2 / 8 Part 1 - Entity and announcement details 1.1 Name of entity RADIOPHARM THERANOSTICS LIMITED We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules. 1.2 Registered number type ACN Registration number 647877889 1.3 ASX issuer code RAD 1.4 The announcement is 1.5 Date of this announcement 17/9/2026 New announcement Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 3 / 8 Part 2 - Type of Issue 2.1 The +securities to be quoted are: Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue. 2.2 The +class of +securities to be quoted is: 2.3c Have these +securities been offered under a +disclosure document or +PDS? 2.3c.1 Date of +disclosure document or +PDS? 30/7/2026 2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B Appendix 3B issued 24 July 2026 including new class of option to be quoted Yes New +securities in a class that is not yet quoted on ASX ("new class") New +securities in a class that is not yet quoted on ASX ("new class") Additional +securities in a class that is already quoted on ASX ("existing class") Other Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 4 / 8 Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B Additional +securities to be quoted in an existing class ASX +security code and description RAD : ORDINARY FULLY PAID Issue date 17/9/2026 Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class? Issue details Number of +securities to be quoted 40,000,000 Are the +securities being issued for a cash consideration? In what currency is the cash consideration being paid? AUD - Australian Dollar What is the issue price per +security? AUD 0.01500000 Any other information the entity wishes to provide about the +securities to be quoted Second Tranche Placement Shares announced 24 July 2026 and approved by shareholders at EGM held 11 September 2026 The purpose(s) for which the entity is issuing the securities Other Please provide additional details The proceeds will primarily be used to fund drug manufacturing, clinical trials and working capital Yes Yes Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 5 / 8 Part 3C - number and type of +securities to be quoted (new class) where issue has not previously been notified to ASX in an Appendix 3B New +securities ASX +security code New class - code to be confirmed +Security description OPTION EXPIRING 31-JUL-2029 EX 0.018 +Security type Options ISIN code Issue date 17/9/2026 Will all the +securities issued in this class rank equally in all respects from the issue date? Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1? Distribution Schedule Provide a distribution schedule for the new +securities according to the categories set out in the left hand column - including the number of recipients and the total percentage of the new +securities held by the recipients in each category. Number of +securities held Number of holders Total percentage of +securities held For example, to enter a value of 50% please input as 50.00 1 - 1,000 % 1,001 - 5,000 % 5,001 - 10,000 % 10,001 - 100,000 1 0.01 % 100,001 and over 135 99.99 % Options Details +Security currency AUD - Australian Dollar Exercise price AUD 0.01800000 Expiry date 31/7/2029 No Yes Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 6 / 8 Details of the type of +security that will be issued if an option is exercised RAD : ORDINARY FULLY PAID Number of +securities that will be issued if an option is exercised One RAD ordinary full paid share for each option exercised Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities to be quoted or provide the information by separate announcement. Prospectus dated 30 July 2026 https://asx.api.cmfyapp.com/asx-research/1.0/file/2924-03116015-2A1686719&v=undefined Issue details Number of +securities to be quoted 448,839,531 Are the +securities being issued for a cash consideration? Please describe the consideration being provided for the +securities Attaching options per announcement dated 24 July 2026 approved by shareholders at EGM held 11 September 2026 Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted 0.000000 Any other information the entity wishes to provide about the +securities to be quoted The purpose(s) for which the entity is issuing the securities Other Please provide additional details The proceeds will primarily be used to fund drug manufacturing, clinical trials and working capital. No Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 7 / 8 Part 4 - Issued capital following quotation Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application) ASX +security code and description Total number of +securities on issue RADO : OPTION EXPIRING 30-NOV-2026 79,352,040 RAD : ORDINARY FULLY PAID 4,377,549,491 RADOB : OPTION EXPIRING 31-OCT-2027 1,179,266,658 New class - code to be confirmed : OPTION EXPIRING 31-JUL-2029 EX 0.018 448,839,531 4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description Total number of +securities on issue RADAK : OPTION EXPIRING 01-JUN-2027 EX $0.60 1,666,500 RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES 387,179,525 RADAJ : OPTION EXPIRING 01-JUL-2027 EX $0.17 12,425,675 RADAF : OPTION EXPIRING 25-NOV-2026 RESTRICTED 8,666,678 RADAG : OPTION EXPIRING 25-NOV-2026 EX $0.60 5,066,672 RADAI : OPTION EXPIRING 27-MAY-2027 EX $0.60 740,000 RADAP : OPTION EXPIRING 24-APR-2028 EX $0.09 8,955,224 Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 8 / 8 Part 5 - Other Listing Rule requirements 5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1? 5.1a Select the number of the applicable exception in Listing Rule 7.2 17 Yes